1
|
Abstract
Multi-omics strategies are indispensable tools in the search for new anti-tuberculosis drugs. Omics methodologies, where the ensemble of a class of biological molecules are measured and evaluated together, enable drug discovery programs to answer two fundamental questions. Firstly, in a discovery biology approach, to find new targets in druggable pathways for target-based investigation, advancing from target to lead compound. Secondly, in a discovery chemistry approach, to identify the mode of action of lead compounds derived from high-throughput screens, progressing from compound to target. The advantage of multi-omics methodologies in both of these settings is that omics approaches are unsupervised and unbiased to a priori hypotheses, making omics useful tools to confirm drug action, reveal new insights into compound activity, and discover new avenues for inquiry. This review summarizes the application of Mycobacterium tuberculosis omics technologies to the early stages of tuberculosis antimicrobial drug discovery.
Collapse
|
2
|
Kuhn ML, Alexander E, Minasov G, Page HJ, Warwrzak Z, Shuvalova L, Flores KJ, Wilson DJ, Shi C, Aldrich CC, Anderson WF. Structure of the Essential Mtb FadD32 Enzyme: A Promising Drug Target for Treating Tuberculosis. ACS Infect Dis 2016; 2:579-591. [PMID: 27547819 DOI: 10.1021/acsinfecdis.6b00082] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Mycolic acids are indispensible lipids of Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB), and contribute to the distinctive architecture and impermeability of the mycobacterial cell envelope. FadD32 plays a pivotal role in mycolic acid biosynthesis by functionally linking fatty acid synthase (FAS) and polyketide synthase (PKS) biosynthetic pathways. FadD32, a fatty acyl-AMP ligase (FAAL), represents one of the best genetically and chemically validated new TB drug targets. We have determined the three-dimensional crystal structure of Mtb FadD32 in complex with a ligand specifically designed to stabilize the catalytically active adenylate-conformation, which provides a foundation for structure-based drug design efforts against this essential protein. The structure also captures the unique interactions of a FAAL-specific insertion sequence and provides insight into the specificity and mechanism of fatty acid transfer.
Collapse
Affiliation(s)
- Misty L. Kuhn
- Center for Structural
Genomics of Infectious Diseases, Department of Biochemistry and Molecular
Genetics, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, United States
- Department of Chemistry and Biochemistry, San Francisco State University, San Francisco, California 94132, United States
| | | | - George Minasov
- Center for Structural
Genomics of Infectious Diseases, Department of Biochemistry and Molecular
Genetics, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, United States
| | - Holland J. Page
- Department of Chemistry and Biochemistry, San Francisco State University, San Francisco, California 94132, United States
| | - Zdzislaw Warwrzak
- LS-CAT,
Synchrotron Research Center, Northwestern University, Argonne, Illinois 60439, United States
| | - Ludmilla Shuvalova
- Center for Structural
Genomics of Infectious Diseases, Department of Biochemistry and Molecular
Genetics, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, United States
| | - Kristin J. Flores
- Center for Structural
Genomics of Infectious Diseases, Department of Biochemistry and Molecular
Genetics, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, United States
| | | | | | | | - Wayne F. Anderson
- Center for Structural
Genomics of Infectious Diseases, Department of Biochemistry and Molecular
Genetics, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, United States
| |
Collapse
|